EToH Seminar Series: "Harnessing the tumor immune microenvironment to combat disease progression"
On Wednesday, February 1, 2023, Daniela Quail, PhD, Assistant Professor at the Department of Physiology and Researcher at the Rosalind and Morris Goodman Cancer Institute, McGill University, will be giving a talk entitled “Harnessing the tumor immune microenvironment to combat disease progression” as part of the Emerging Topics of Health (EToH) Seminar series, cohosted by the Departments of Microbiology and Immunology, Physiology and Human Genetics, the Rosalind and Morris Goodman Cancer Institute, the McGill University Research Centre on Complex Traits (MRCCT) and M[i]4.
There will be a 5à7 after the talk at Brass Doors Pub (2171 Crescent Street) and anyone (students, postdocs, and faculty) are welcome to join!
Grad students and postdocs
Sign up to have lunch with our guest speaker! If you would like to have lunch with our guest speaker, please fill out this SURVEY. The lunch will be held from 12h to 1h in Room #530 in the Bellini.
Abstract
The tumor immune microenvironment (TIME) strongly influences disease progression, from primary tumor growth to establishment of metastatic lesions. As clinical applications for immunotherapy are on the rise, understanding how to harness the immune system to combat cancer at different stages of disease is gaining significant attention in research. Many of these research efforts have been focused on the adaptive immune system, yet there is untapped translational value in leveraging innate effector functions within the myeloid compartment, which is highly abundant within tumours. The Quail lab studies the regulatory mechanisms of myeloid maturation and recruitment into tumours, and tests the hypothesis that targeting specific myeloid states in cancer can be effective against disease progression. By utilizing highly multiplex immune profiling technologies, we are able to gain insight into the vast heterogeneity of myeloid identities within tissues, with the goal of unveiling new strategies to target myeloid populations and enhance immunotherapy responses.
